Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.48 |
| ▸ | CNR1 | P21554 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 4/20 | 0.43 |
| ▸ | BRD2 | P25440 | 4/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30899260 | 0.94 | CNR2 (0.44) | CNR2CNR1POLBSMN1; SMN2BRD4 | |
| SCHEMBL24512122 | 0.94 | CNR2 (0.44) | CNR2CNR1POLBSMN1; SMN2BRD4 | |
| SCHEMBL30899268 | 0.89 | CNR1 (0.43) | CNR2CNR1POLBSMN1; SMN2BRD4 | |
| SCHEMBL24512244 | 0.89 | CNR1 (0.43) | CNR2CNR1POLBSMN1; SMN2BRD4 | |
| SCHEMBL29717121 | 0.88 | CNR1 (0.46) | CNR2CNR1POLBSMN1; SMN2BRD4 | |
| SCHEMBL24512148 | 0.88 | CNR1 (0.46) | CNR2CNR1POLBSMN1; SMN2BRD4 | |
| SCHEMBL30899264 | 0.88 | CNR1 (0.43) | CNR2CNR1POLBSMN1; SMN2BRD4 | |
| SCHEMBL29717201 | 0.88 | LMNA (0.55) | CNR2CNR1SMN1; SMN2BRD4BRD2 | |
| SCHEMBL29717142 | 0.88 | LMNA (0.52) | CNR2CNR1SMN1; SMN2BRD4BRD2 | |
| SCHEMBL29717169 | 0.86 | BRD4 (0.54) | CNR2CNR1SMN1; SMN2BRD4BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117915903-A | Compounds for the treatment of neurodegenerative, degenerative and metabolic disorders and uses thereof | 佛罗里达大学研究基金会公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124466-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SNCA, NLN, HTT | CNR2 1971/4885CNR1 1702/4885POLB 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.